Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05205980 · ClinicalTrials.gov registry record · NA
Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)
A NA study of Alzheimer Disease, sponsored by Georgia State University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05205980: Recruiting NA study of Alzheimer Disease, sponsored by Georgia State University.
NCT05205980 is a NA study of Alzheimer Disease that is actively recruiting participants, run by Georgia State University. The registered enrollment target is 30 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05205980, a NA study of Alzheimer Disease, is actively recruiting participants, sponsored by Georgia State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.
Primary Outcome
The outcome of each perturbation trial will be determined as a fall if the peak load cell force exceeds 30% of the body weight. The load cell records the force applied to the human body by the safety harness system after a perturbation. The lab-induced faller rate will be calculated as the ratio of the number of fallers to the number of participants within each group.
Conditions Studied
Interventions
- BEHAVIORAL Perturbation training
Study Locations (1)
Georgia
- Reminiscent - Valdosta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2026-10-30 |
| Phase | NA |
What NCT05205980 shows while recruiting
NCT05205980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Perturbation training is the first listed.
NCT05205980 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05205980 about?
NCT05205980 is a clinical study titled "Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)". This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.
What is the current status of trial NCT05205980?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-04-28. Estimated completion is 2026-10-30.
What conditions does trial NCT05205980 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05205980?
The interventions under investigation include: Perturbation training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05205980?
This trial is sponsored by Georgia State University, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05205980 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05205980's enrollment target sits among peer trials
30 239th of 306 higher than 56 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI